| # | Drug | Count |
|---|---|---|
| 0 | GLATIRAMER ACETATE | 111 |
| 1 | OFATUMUMAB | 104 |
| 2 | ADALIMUMAB | 88 |
| 3 | ETANERCEPT | 77 |
| 4 | OMALIZUMAB | 75 |
| 5 | ERGOCALCIFEROL | 68 |
| 6 | METHOTREXATE SODIUM | 66 |
| 7 | METHOTREXATE | 60 |
| 8 | USTEKINUMAB | 60 |
| 9 | ALBUTEROL SULFATE | 48 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | PEGULICIANINE | 1 | 0.1250 |
| 1 | DEXTROMETHORPHAN HBR AND PYRILAMINE MALEATE | 1 | 0.0588 |
| 2 | OMALIZUMAB-IGEC | 1 | 0.0112 |
| 3 | OCRELIZUMAB AND HYALURONIDASE | 5 | 0.0100 |
| 4 | FLORBETAPIR F 18 | 1 | 0.0087 |
| 5 | INDOCYANINE GREEN | 1 | 0.0083 |
| 6 | MULTIPLE VITAMINS INJECTION | 1 | 0.0061 |
| 7 | PEGFILGRASTIM-APGF | 1 | 0.0051 |
| 8 | GLYCERIN SUPPOSITORY | 12 | 0.0045 |
| 9 | GLYCERIN SUPPOSITORIES | 12 | 0.0045 |
| # | Drug class | Count |
|---|---|---|
| 0 | CD20-directed Cytolytic Antibody [EPC] | 151 |
| 1 | Tumor Necrosis Factor Blocker [EPC] | 126 |
| 2 | Corticosteroid [EPC] | 112 |
| 3 | Nonsteroidal Anti-inflammatory Drug [EPC] | 105 |
| 4 | Interleukin-23 Antagonist [EPC] | 89 |
| 5 | Anti-IgE [EPC] | 75 |
| 6 | Provitamin D2 Compound [EPC] | 68 |
| 7 | Interleukin-12 Antagonist [EPC] | 60 |
| 8 | Folate Analog Metabolic Inhibitor [EPC] | 59 |
| 9 | Interleukin-17A Antagonist [EPC] | 58 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 22 | 0.0320 |
| 1 | Endoglycosidase [EPC] | 33 | 0.0178 |
| 2 | CD38-directed Cytolytic Antibody [EPC] | 38 | 0.0065 |
| 3 | Provitamin D2 Compound [EPC] | 68 | 0.0023 |
| 4 | Tissue-nonspecific Alkaline Phosphatase [EPC] | 23 | 0.0022 |
| 5 | Sclerosing Agent [EPC] | 1 | 0.0022 |
| 6 | Interleukin-17A Antagonist [EPC] | 58 | 0.0016 |
| 7 | Diagnostic Dye [EPC] | 1 | 0.0015 |
| 8 | PCSK9 Inhibitor [EPC] | 39 | 0.0015 |
| 9 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 6 | 0.0015 |